Group behind caregiver crackdown urges cannabis businesses to offer free or low-cost products to seriously ill patients 

click to enlarge Medical cannabis. - SHUTTERSTOCK
  • Shutterstock
  • Medical cannabis.

The Michigan Cannabis Manufacturers Association is encouraging its members to provide free or low-cost cannabis products to patients with severe or terminal illnesses.
MCMA’s Board of Directors unanimously passed a resolution last week that asks member companies to create a program to ensure seriously ill patients have access to low- or no-cost cannabis products that are tested, labeled, tracked, and licensed.

MCMA represents cannabis businesses across the state.

“Just like any other form of medicine, patients with cancer and other severe or terminal illnesses deserve to know their cannabis has met the highest standards for testing, tracking, licensing and safety — and our members’ products do just that,” MCMA Executive Director Stephen Linder said in a news release. “Michigan’s patients rely on cannabis as medicine and deserve to know where their cannabis comes from and what’s in it. We encourage our member companies to assess the specific needs of these patients in their communities and help ensure they have access to safe, tested cannabis products.”

Here’s the resolution:

The Board of Directors of the Michigan Cannabis Manufacturers Association hereby resolves: The membership of the MCMA is committed to making sure that patients and children with chronic illnesses such as cancer, autoimmune diseases, autism, and many other chronic or terminal illnesses should have access to safe, tested and cost-effective medical cannabis products.

Therefore, be it resolved, that the Board of the Michigan Cannabis Manufacturers Association encourages each member to develop their own program to offer low-cost or free Medical Cannabis and Medical products and develop the criteria to do so and advertise their program independently to the public.

The Board of the MCMA is taking the Best Practice from the Regulated Pharmaceutical Industry to assist Americans in obtaining the medicine they need by offering these life-saving drugs at an affordable cost to the most vulnerable citizens.

The Board of the MCMA is proud to emulate this compassionate program and to provide Medical Cannabis products that are tested, safe and of the highest quality and purity to treat children and those with chronic or terminal illnesses.

MCMA has come under fire for supporting legislation that would license and regulate medical marijuana caregivers. Some opponents are calling for a boycott of MCMA’s members, saying the legislation is intended to monopolize the industry.

Stay connected with Detroit Metro Times. Subscribe to our newsletters, and follow us on Google News, Apple News, Twitter, Facebook, Instagram, or Reddit.

We welcome readers to submit letters regarding articles and content in Detroit Metro Times. Letters should be a minimum of 150 words, refer to content that has appeared on Detroit Metro Times, and must include the writer's full name, address, and phone number for verification purposes. No attachments will be considered. Writers of letters selected for publication will be notified via email. Letters may be edited and shortened for space.

Email us at [email protected].

Support Local Journalism.
Join the Detroit Metro Times Press Club

Local journalism is information. Information is power. And we believe everyone deserves access to accurate independent coverage of their community and state. Our readers helped us continue this coverage in 2020, and we are so grateful for the support.

Help us keep this coverage going in 2021. Whether it's a one-time acknowledgement of this article or an ongoing membership pledge, your support goes to local-based reporting from our small but mighty team.

Join the Metro Times Press Club for as little as $5 a month.

Read the Digital Print Issue

January 26, 2022

View more issues


Never miss a beat

Sign Up Now

Subscribe now to get the latest news delivered right to your inbox.

Best Things to Do In Detroit

© 2022 Detroit Metro Times - Contact Us

Website powered by Foundation